Physician profile
Udayashree Nune
NPI 1295729523
$1,236.85
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $92.09 · 2021: $2.78 · 2022: $42.48 · 2023: $237 · 2024: $122 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $241.53 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $177.82 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $71.38 | 2019 | |
| Pfizer INC. | $70.46 | 2019 | |
| Abbvie INC. | $63.05 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.21 | 2019-2020 | |
| Dexcom, INC. | $40.09 | 2022-2023 | Dexcom G6 Transmitter |
| Kvk-Tech, INC. | $31.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.68 | 2023 | |
| Glaxosmithkline, LLC. | $25.66 | 2020-2024 | Trelegy Ellipta |
| Mylan Specialty L.P. | $21.18 | 2019 | |
| Merck Sharp & Dohme LLC | $16.28 | 2019 | |
| Exact Sciences Corporation | $15.19 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udayashree Nune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.